Epitalon Research: What Published Studies Have Investigated

What is Epitalon?

What is Epitalon? It is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (often abbreviated “AEDG”), developed at the St Petersburg Institute of Bioregulation and Gerontology as a short-peptide analog derived from epithalamin, a peptide preparation of the pineal gland. It was introduced by Khavinson and colleagues as a “bioregulator” and has been studied as a purported telomerase activator and geroprotector. The spelling equivalence matters: Epithalon and Epitalon name the same AEDG tetrapeptide. That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people.

Molecule properties

Epitalon is a short peptide of just four amino acid residues (Ala-Glu-Asp-Gly), which places it in the class of short / oligopeptide “bioregulators” that the St Petersburg group catalogued. A key distinction runs through the whole literature: the modern research compound is a synthetic tetrapeptide, whereas its historical parent, epithalamin, was a pineal-gland extract — a mixture rather than a defined single peptide. In research catalogues Epitalon is supplied as a lyophilized powder, which is why it is handled as a research peptide with a defined sequence and molecular identity. These are molecule facts only — no handling, reconstitution, or injection instructions are given here.

Mechanisms researchers have examined

The Epitalon mechanism literature centres on telomere biology, with additional neuroendocrine and stability endpoints. Each direction below is framed as what researchers examined, characterized primarily in cell culture and rodent models:

• Telomerase (hTERT) induction in cultured cells — Khavinson, Bondarev & Butyugov (2003, Bull Exp Biol Med, PMID 12937682) reported that adding the peptide to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit (hTERT), telomerase enzymatic activity, and telomere elongation in vitro. This is strictly an in-vitro observation from the originating group.
• Independent in-vitro re-examination — Al-dulaimi et al. (2025, Biogerontology, PMC12411320) reported dose-dependent telomere lengthening across several human cell lines, via hTERT / telomerase upregulation in normal cells and alternative-lengthening-of-telomeres (ALT) activity in cancer lines. The authors describe it as a 2D in-vitro study and call for 3D and animal follow-up. It is the notable independent signal that partially corroborates the original telomerase claim while remaining preclinical.
• Pineal / circadian and neuroendocrine signalling — the epithalamin / Epitalon line of work examined melatonin-rhythm and neuroendocrine parameters in animal models. This is described as a studied mechanism area, not an outcome.
• Antioxidant / chromosomal-stability endpoints — animal studies examined markers such as chromosome-aberration frequency in bone-marrow cells (Anisimov 2003, cited below).

The section closes as the literature does: the described mechanisms are characterized primarily in cell culture and rodent models, and the telomerase findings rest heavily on a single originating group. Each bullet names a pathway examined, not an effect in a reader.

Research models in the literature

Preclinical models dominate the record. On the cell-culture side, cultured human fibroblasts and a mix of cancer and normal cell lines carry the telomerase / ALT work described above. On the animal side, Anisimov et al. (2003, Biogerontology, PMID 14501183) examined biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice; the paper reported reduced chromosome-aberration frequency and reduced spontaneous tumor incidence, while noting no change in mean body weight or food intake and only a modest survival signal. Kossoy, Anisimov et al. (2006, In Vivo, PMID 16634527) examined spontaneous carcinogenesis in female C3H/He mice.

Human-relevant work is limited to small, non-blinded, non-randomized clinical programs from the same group (for example, Korkushko and colleagues). Described neutrally, these programs exist — but they are not blinded randomized controlled trials and have not been independently replicated, so they can be referenced only as evidence-limitation context and never as a demonstrated benefit. The overall picture is that the interventional human evidence base is minimal and methodologically limited, and that animal or in-vitro findings cannot establish human outcomes.

Provenance and the state of the evidence

The single-group caveat deserves stating directly: the large majority of the Epitalon literature originates from Khavinson, Anisimov and colleagues at the St Petersburg Institute of Bioregulation and Gerontology, much of it in lower-impact or Russian-language venues, with limited independent replication and recognized methodological concerns. The 2025 Al-dulaimi in-vitro study is the main exception that offers some independent corroboration of the telomerase signal, and it too is preclinical. The honest framing is that the record is interesting but unsettled. A reader should treat the telomerase and geroprotector mechanism claims as hypotheses under investigation, not as established facts — and certainly not as a promise of any effect in a person.

Epitalon among the peptide bioregulators

As a research target, Epitalon is usually positioned against epithalamin, its pineal-extract parent: where epithalamin is a mixed gland preparation, Epitalon is the defined synthetic AEDG tetrapeptide, and that shift from extract to single sequence is much of what distinguishes it in the broader short-peptide “bioregulator” research program. This is family context — a research-focus comparison, not stacking or use advice. Beyond that contrast the detail belongs on adjacent pages: for another longevity-adjacent research explainer, see NAD+ research, and for a mitochondrial-derived peptide studied in aging models, see MOTS-c research. This page deliberately hands off rather than rebuilding those literatures here.

Research-grade sourcing and verification

For laboratory research use only, Epitalon is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is sourcing and identity-assurance framing only — quality for research use, not outcomes.

Frequently asked questions

Literature cited

1. Khavinson VKh, Bondarev IE, Butyugov AA. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592. PMID 12937682.
2. Anisimov VN, Khavinson VKh, et al. “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.” Biogerontology. 2003;4(4):193–202. PMID 14501183.
3. Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. “Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice.” In Vivo. 2006;20(2):253–257. PMID 16634527.
4. Al-dulaimi S, Thomas R, Matta S, Roberts T. “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Biogerontology. 2025;26(5):178. PMC12411320 (independent in-vitro study; 2D culture; authors call for 3D / animal follow-up).
5. Korkushko OV, Khavinson VKh, et al. Long-term epithalamin / Epitalon programs in older adults. Bulletin of Experimental Biology and Medicine / Neuroendocrinology Letters. 2000s (small, non-blinded, non-randomized, single-group; not independently replicated RCTs — cited only as evidence-limitation context).